# US 10,441,606 B2 · Polymers for reversing heparin-based anticoagulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,441,606 B2
- Document ID: US10441606B2
- Status: Granted
- Kind: B2
- Application number: 15/887,561
- Filed: 2018-02-02
- Published: 2018-08-02
- Granted: 2019-10-15
- Earliest claimed: 2011-06-01
- Assignees: The University of British Columbia
- Applicants: University of British Columbia
- Inventors: Jayachandran N. Kizhakkedathu; Rajesh A. Shenoi; Cedric J. Carter; Donald E. Brooks
- Web page: https://patentgrep.com/patent/US10441606B2

## CPC

- A61K 31/795: Polymers containing sulfur
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 31/765: Polymers containing oxygen
- A61K 31/785: Polymers containing nitrogen
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61M 1/3675: {Deactivation}
- A61M 1/3679: {by absorption (A61M1/3675 takes precedence)}
- B01D 15/36: involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
- C08G 73/024: {Polyamines containing oxygen in the form of ether bonds in the main chain}
- C08L 71/02: Polyalkylene oxides
- A61M 2202/0021: removed from and reintroduced into the body, e.g. after treatment
- A61M 2202/0413: Blood
- A61M 2202/0478: Heparin
- C08G 2340/00: Filter material
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- B01D: SEPARATION (separating solids from solids by wet methods B03B, B03D; by pneumatic jigs or tables B03B; by other dry methods B07; magnetic or electrostatic separation of solid materials from solid materials or fluids, separation by high-voltage electric fields B03C; centrifuges, vortex apparatus B04; presses per se for squeezing-out liquid from liquid-containing material B30B9/02; treatment of water C02F, e.g. softening by ion-exchange C02F1/42; {arrangements of air intake cleaners in gas turbine plants F02C7/05} ; arrangements or mounting of filters in air-conditioning, air-humidification or ventilation F24F13/28)
- C08G: MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06)

## Abstract

Embodiments presented herein relate to various polymers. Some of the polymer embodiments are heparin binding polymers. Some embodiments of the heparin binding polymers can be employed to bind to heparin for methods such as separating, purifying, removing, and/or isolating heparin and heparin like molecules.

## Claims

### Claim 1

A method of counteracting heparin in a subject, the method comprising:
administering a heparin binding polymer to the subject, wherein the heparin binding polymer comprises:
a core unit, wherein the core unit comprises a C1-18 alkyl substituted with three or more of —OR1,
wherein each R1 is independently selected from a polymer segment having monomer units of Formula (III):
wherein n is an integer from 1 to 10,000;
wherein each R2 is independently selected from a hydrogen, carbon, a cationic moiety, R1, and a polymer segment of Formula (IV):
wherein each R3 is independently selected from an oxygen cationic moiety, a hydroxyl, and a polymer segment of Formula (IV),
wherein m is an integer from 1 to 10,000
wherein each R4 is independently selected from a C1-6 alkoxy,
wherein the heparin binding polymer comprises 16 to 25 cationic moieties, wherein the cationic moieties have a positive charge when the heparin binding polymer is at a physiological pH,
wherein the cationic moieties are of Formula (VI):
and wherein the molecular weight of the heparin binding polymer is about 20 kDa to 25 kDa.

### Claim 2 (depends on 1)

The method of claim 1, wherein the core unit is a compound of Formula (V):

### Claim 3 (depends on 1)

The method of claim 1, wherein the polymer segment of Formula (IV):
comprises polyethylene glycol having a size of 400 Da.

### Claim 4 (depends on 1)

The method of claim 1, wherein at least one polymer segment of Formula (IV):
in the heparin binding polymer is polyethylene glycol.

### Claim 5 (depends on 1)

The method of claim 1, further comprising identifying a subject who has received an excess amount of heparin, wherein the identifying occurs before the heparin binding polymer is administered to the subject.

### Claim 6 (depends on 1)

The method of claim 1, wherein the heparin binding polymer is administered subcutaneously.

### Claim 7 (depends on 1)

The method of claim 1, wherein the heparin binding polymer is administered intravenously.

### Claim 8 (depends on 1)

The method of claim 1, wherein the heparin binding polymer binds to heparin selected from at least one of: unfractionated heparin (UFH), low molecular weight heparin (LMWH), ultra-low molecular weight heparin (ULMWH), fondaparinux, idraparinux enoxaparin, dalteparin, tinzaparin, semuloparin, or heparinoid.

### Claim 9

A method of counteracting heparin in a subject, the method comprising:
administering a heparin binding polymer to the subject, wherein the heparin binding polymer comprises:
a core unit, wherein the core unit comprises a C1-18 alkyl substituted with three or more of —OR1,
wherein each R1 is independently selected from a polymer segment having monomer units of Formula (III):
wherein n is an integer from 1 to 10,000;
wherein each R2 is independently selected from a hydrogen, carbon, a cationic moiety, R1, and a polymer segment of Formula (IV):
wherein each R3 is independently selected from an oxygen cationic moiety, a hydroxyl, and a polymer segment of Formula (IV),
wherein m is an integer from 1 to 10,000
wherein each R4 is independently selected from a C1-6 alkoxy,
wherein the heparin binding polymer comprises 4 to 24 cationic moieties, wherein the cationic moieties have a positive charge when the heparin binding polymer is at a physiological pH,
wherein the cationic moieties are of Formula (VI):
and wherein the molecular weight of the heparin binding polymer is about 20 kDa to 25 kDa.